Alison W Rebman Selected Research

Anti-Bacterial Agents (Antibiotics)

8/2023	Outpatient visits before and after Lyme disease diagnosis in a Maryland employer-based health plan.
1/2022	A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease.
10/2021	Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome.
8/2021	The presenting characteristics of erythema migrans vary by age, sex, duration, and body location.
1/2020	Risk Factors and Outcomes of Treatment Delays in Lyme Disease: A Population-Based Retrospective Cohort Study.
1/2020	A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients.
1/2019	Molecular Testing of Serial Blood Specimens from Patients with Early Lyme Disease during Treatment Reveals Changing Coinfection with Mixtures of Borrelia burgdorferi Genotypes.
3/2017	Standardized Symptom Measurement of Individuals with Early Lyme Disease Over Time.
1/2017	The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome.
2/2016	Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alison W Rebman Research Topics

Disease

20	Lyme Disease (Disease, Lyme) 04/2024 - 01/2012
9	Post-Lyme Disease Syndrome 04/2024 - 12/2018
6	Erythema 01/2024 - 01/2012
5	Infections 04/2024 - 12/2015
2	Tick-Borne Diseases (Tick-Borne Disease) 12/2020 - 02/2016
2	Exanthema (Rash) 12/2020 - 08/2012
2	Pain (Aches) 01/2020 - 03/2017
2	Fatigue 01/2020 - 03/2017
1	COVID-19 04/2024
1	Bacterial Infections (Bacterial Infection) 11/2022
1	Inflammation (Inflammations) 01/2022
1	Multiple Sclerosis 01/2022
1	Neuromyelitis Optica (Devic's Disease) 01/2022
1	Neurologic Manifestations (Neurological Manifestations) 01/2021
1	Cognitive Dysfunction 03/2017
1	Chronic Disease (Chronic Diseases) 02/2016

Drug/Important Bio-Agent (IBA)

13	Anti-Bacterial Agents (Antibiotics)IBA 08/2023 - 01/2012
7	AntibodiesIBA 04/2024 - 12/2015
5	Biomarkers (Surrogate Marker)IBA 11/2022 - 02/2016
2	AutoantibodiesIBA 04/2024 - 01/2022
2	Doxycycline (Periostat)FDA LinkGeneric 01/2019 - 03/2015
2	AntigensIBA 01/2018 - 12/2015
2	Immunoglobulin G (IgG)IBA 12/2015 - 08/2012
1	Annexin A2 (Annexin II)IBA 01/2024
1	mirfentanilIBA 01/2022
1	Protein-Arginine DeiminasesIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	VaccinesIBA 12/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Blood Proteins (Serum Proteins)IBA 01/2020
1	Staphylococcal Protein A (Protein A)IBA 12/2018
1	ChemokinesIBA 09/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 12/2015
1	Immunoglobulin M (IgM)IBA 12/2015
1	Peptides (Polypeptides)IBA 12/2015
1	DNA (Deoxyribonucleic Acid)IBA 01/2012

Therapy/Procedure

6	Aftercare (After-Treatment) 08/2023 - 02/2016
5	Therapeutics 01/2019 - 01/2012
2	Ambulatory Care (Outpatient Care) 08/2023 - 01/2020
2	Time-to-Treatment 01/2023 - 01/2020
1	Treatment Delay 01/2020